SEARCH

SEARCH BY CITATION

References

  • 1
    Heisel O, Heisel R, Balshaw R, Keown P. New onset diabetes mellitus in patients receiving calcineurin inhibitors: A systematic review and meta-analysis. Am J Transplant 2004; 4: 583595.
  • 2
    Tueche SG. Diabetes mellitus after liver transplant new etiologic clues and cornerstones for understanding. Transplant Proc 2003; 35: 14661468.
  • 3
    Blanco JJ, Herrero JI, Quiroga J, Sangro B, Gomez-Manero N, Pardo F, et al. Liver transplantation in cirrhotic patients with diabetes mellitus: Midterm results, survival and adverse events. Liver Transpl 2001; 7: 226233.
  • 4
    Yoo HY, Thuluvath PJ. The effect of insulin-dependent diabetes mellitus on outcome of liver transplantation. Transplantation 2002; 74: 10071012.
  • 5
    John PR, Thuluvath PJ. Outcome of liver transplantation in patients with diabetes mellitus: A case-control study. Hepatology 2001; 34: 889895.
  • 6
    The US Multicenter FK506 Liver Study Group. A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 1994; 331; 11101115.
  • 7
    European FK506 Multicentre Liver Study Group. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. Lancet 1994; 344: 423428.
  • 8
    Stegall MD, Wachs ME, Everson G, Steinberg T, Bilir B, Shrestha R, et al. Prednisone withdrawal 14 days after liver transplantation with mycophenolate: A prospective trial of cyclosporine and tacrolimus. Transplantation 1997; 64: 17551760.
  • 9
    American Diabetes Association. Report of the Expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003; 26(Suppl): S5S20.
  • 10
    Trail KC, McCashland TM, Larsen JL, Heffron TG, Stratta RJ, Langnas AN, et al. Morbidity in patients with posttransplant diabetes mellitus following orthotopic liver transplantation. Liver Transpl Surg 1996; 2: 276283.
  • 11
    John PR, Thuluvath PJ. Outcome of patients with new-onset diabetes mellitus after liver transplantation compared with those without diabetes mellitus. Liver Transpl 2002; 8: 708713.
  • 12
    Baid S, Cosimi AB, Farrell ML, Schoenfeld DA, Feng S, Chung RT, et al. Posttransplant diabetes mellitus in liver transplant recipients: Risk factors, temporal relationship with hepatitis C virus allograft hepatitis, and impact on mortality. Transplantation 2001; 72: 10661072.
  • 13
    Navasa M, Bustamante J, Marroni C, González E, Andreu H, Esmatjes E, et al. Diabetes mellitus after liver transplantation: Prevalence and predictive factors. J Hepatol. 1996; 25: 6471.
  • 14
    Steinmuller TM, Stockmann M, Bechstein WO, Settmacher U, Jonas S, Neuhaus P. Liver transplantation and diabetes mellitus. Exp Clin Endocrinol Diabetes 2000; 108: 401405.
  • 15
    Steinmuller TM, Graf K-J, Schleicher J, Leder K, Bechstein WO, Mueller AR, et al The effect of FK506 versus cyclosporine on glucose and lipid metabolism—a randomized trial. Transplantation 1994; 58: 669674.
  • 16
    Stockmann M, Steinmuller T, Nolting S, Neuhaus P. Posttransplant diabetes mellitus after orthotopic liver transplantation. Transplant Proc 2002; 34: 15711572.
  • 17
    AlDosary AA, Ramji AS, Elliott TG, Sirrs SM, Thompson DM, Erb SR, et al. Postliver transplant diabetes mellitus: An association with hepatitis C. Liver Transplant 2002; 8: 356361.
  • 18
    Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003; 3: 178185.
  • 19
    Sumrani NB, Delaney V, Ding ZK, Davis R, Daskalakis P, Friedman EA, et al. Diabetes mellitus after renal transplantation in the cyclosporine era—an analysis of risk factors. Transplantation 1991; 51: 343347.
  • 20
    Bigam DL, Pennington JJ, Carpentier A, Wanless IR, Hemming AW, Croxford R, et al. Hepatitis C-related cirrhosis: A predictor of diabetes after liver transplantation. Hepatology 2000; 32: 8790.
  • 21
    Knobler H, Schihmanter R, Zifroni A, Fenakel G, Schattner A. Increased risk of type 2 diabetes in noncirrhotic patients with chronic hepatitis C virus infection. Mayo Clin Proc 2000; 75: 355359.
  • 22
    Delgado-Borrego A, Casson D, Schoenfeld D, Somsouk M, Terella A, Jordan SH, et al. Hepatitis C virus is independently associated with increased insulin resistance after liver transplantation. Transplantation 2004; 77: 703710.
  • 23
    Masini M, Campani D, Boggi U, Menicagli M, Funel N, Pollera M, et al. Hepatitis C virus infection and human pancreatic beta-cell dysfunction. Diabetes Care (in press).
  • 24
    Montori VM, Velosa JA, Basu A, Gabriel SE, Erwin PJ, Kudva YC. Posttrasplantation diabetes: A systematic review of the literature. Diabetes Care 2002; 25: 583592.
  • 25
    Chan JC, Cockram CS, Critchley JA. Drug-induced disorders of glucose metabolism. Mechanisms and management. Drug Saf 1996; 15: 135157.
  • 26
    Hjelmesaeth J, Hartmann A, Kofstad J, Stenstrom A, Leivestad T, Egeland T, Fauchald P. Glucose intolerance after renal transplantation depends upon prednisolone dose and recipient age. Transplantation 1997; 64: 979983.
  • 27
    Boudreaux JP, McHugh L, Canafax DM, Ascher N, Sutherland DE, Payne W, et al. The impact of cyclosporine and combination immunosuppression on the incidence of post-transplant diabetes in renal allograft recipients. Transplantation 1987; 44: 376381.
  • 28
    Friedman EA, Shyh T-P, Beyer MM, Manis T, Butt KM. Posttransplant diabetes in kidney transplant recipients. Am J Nephrol 1985; 5: 196202.
  • 29
    Vesco L, Busson M, Bedrossian J, Bitker MO, Hiesse C, Lang P. Diabetes mellitus after renal transplantation: Characteristics, outcome and risk factors. Transplantation 1996; 61: 14751478.
  • 30
    Marchetti P, Navalesi R. The metabolic effects of cyclosporin and tacrolimus. J Endocrinol Invest 2000; 23: 482490.
  • 31
    Drachenberg CB, Klassen DK, Weir MR, Wiland A, Fink JC, Bartlett ST, et al. Islet cell damage associated with tacrolimus and cyclosporine: Morphological features in pancreas allograft biopsies and clinical correlation. Transplantation 1999; 68: 396402.
  • 32
    Woodward RS, Schnitzler MA, Baty J, Lowell JA, Lopez-Rocafort L, Haider S, et al. Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients. Am J Transplant 2003; 3: 590598.
  • 33
    Levy G, Villamil F, Samuel D, Sanjuan F, Grazi GL, Wu Y, et al on behalf of the LIS2T Study Group. Results of LIS2T, a multicenter, randomized study comparing cyclosporine microemulsion with C2 monitoring and tacrolimus with C0 monitoring in de novo liver transplantation. Transplantation 2004; 77: 16321638.
  • 34
    Grazi GL, Levy G, Wu Y, Marotta P, Boillot O, San Juan F, et al. 12-month follow-up data from a randomized, multicentre, prospective study of cyclosporine C2 monitoring versus tacrolimus in liver transplantation. Am J Transplant 2004; 4: 268.
  • 35
    National Cholesterol Education Program (NCEP). Detection, evaluation and treatment of high blood cholesterol in adults: Adult Treatment Panel III. Bethesda, MF. National Institutes of Health, National Heart, Lung and Blood Institute 2002. NIH Publication No. 02-5215.
  • 36
    Davidson J, Wilkinson A, Dantal J, Dotta F, Haller H, Hernández D, et al. New-onset diabetes after transplantation: 2003 international consensus guidelines. Transplantation 2003; 75(Suppl): SS3S24.
  • 37
    DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in IDDM. N Engl J Med 1993; 329: 977986.
  • 38
    UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837853.
  • 39
    Shields PL, Tang H, Neuberger JM, Gunson BK, McMaster P, Pirenne J. Poor outcome in patients with diabetes mellitus undergoing liver transplantation. Transplantation 1999; 68: 530535.
  • 40
    Marchetti P. Strategies for risk reduction and management of posttransplant diabetes mellitus. Transplant Proc 2001; 33(Suppl 5A): 27S31S.
  • 41
    Benhamou PY, Penformis A. Natural history, prognosis, and management of transplantation-induced diabetes mellitus. Diabetes Metab 2002; 28: 166175.
  • 42
    Marchetti P. New-onset diabetes after transplantation. J Heart Lung Transplant 2004; 23(Suppl): S194S201.
  • 43
    American Diabetes Association. Hyperglycemic crises in patients with diabetes mellitus. Diabetes Care 2001; 24: 154161.
  • 44
    Coursin DB, Connery LE, Ketzler JT. Perioperative diabetic and hyperglycemic management issues. Crit Care Med 2004; 32(Suppl 4): S116S125.
  • 45
    Huang ES, Meigs JB, Singer DE. The effect of interventions to prevent cardiovascular disease in patients with type 2 diabetes mellitus. Am J Med 2001; 111: 633642.
  • 46
    Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229234.
  • 47
    Kasiske BL, Chakkera HA, Roel J. Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol 2000; 11: 17351743.
  • 48
    Baid S, Cosimi AB, Tolkoff-Rubin N, Colvin RB, Williams WW, Pascual M. Renal disease associated with hepatitis C infection after kidney and liver transplantation. Transplantation 2000; 70: 255261.
  • 49
    Konrad T, Vicini P, Zeuzem S, Toffolo G, Breim D, Lormann J, et al. Interferon-alpha improves glucose tolerance in diabetes and non-diabetic patients with HCV-induced liver disease. Exp Clin Endocrinol Diabetes 1999; 107: 343349.
  • 50
    Gomez R, Moreno E, Colina F, Loinaz C, Gonzalez-Pinto I, Lumbreras C, et al. Steroid withdrawal is safe and beneficial in stable cyclosporin treated liver transplant patients. J Hepatol 1998; 28: 150156.
  • 51
    Emre S, Genyk Y, Schluger LK, Fishbein TM, Guy SR, Sheiner PA, et al. Treatment of tacrolimus-related adverse effects by conversion to cyclosporin in liver transplant recipients. Transpl Int 2000; 13: 7378.
  • 52
    Abouljoud MS, Kumar A, Brayman KL, Emre S, Bynon JS for the OLN-452 Study Group. Neoral rescue therapy in transplant patients with intolerance to tacrolimus. Clin Transplant 2002; 16: 168172.
  • 53
    Herrero JI, Quiroga J, Sangro B, Pardo F, Rotellar F, Cienfuegos JA, Prieto J. Conversion from calcineurin inhibitors to mycophenolate mofetil in liver transplant recipients with diabetes mellitus. Transplant Proc 2003; 35: 18771879.
  • 54
    Marroni CA, Hoppe L, Diehl JL, Leipnitz I, Brandao AB, Cassal AP, et al. Diabetes mellitus and liver transplantation in adults. Transplant Proc 1999; 31: 3046.
  • 55
    Ericzon B, Groth C, Bismuth H, Calne R, McMaster P, Neuhaus P, et al. Glucose metabolism in liver transplant recipients treated with FK 506 or cyclosporin in the European multicentre study. Transpl Int 1994; 7(Suppl): S11S14.
  • 56
    O'Grady JG, Burroughs A, Hardy P, Elbourne D, Truesdale A and the UK and Republic of Ireland Liver Transplant Study Group. Tacrolimus versus microemulsified ciclosporin in liver transplantation: The TMC randomised controlled trial. Lancet 2002; 360: 11191125.
  • 57
    Lohmann T, List C, Lamesch P, Kohlhaw K, Wenzke M, Schwarz C, et al. Diabetes mellitus and islet cell specific autoimmunity as adverse effects of immunosuppressive therapy by FK506/tacrolimus. Exp Clin Endocrinol Diabetes 2000; 108: 347352.
  • 58
    Jindal RM. Posttransplant diabetes mellitus—a review. Transplantation 1994; 58: 12891298.
  • 59
    Varo E, Padin E, Otero E, Tomé S, Castroagudin JF, Delgado M, et al. Cardiovascular risk factors in liver allograft recipients: Relationship with immunosuppressive therapy. Transplant Proc 2002; 34: 15531554.
  • 60
    Rabkin JM, Rosen HR, Corless CL, Olyaei AJ. Tacrolimus is associated with a lower incidence of cardiovascular complications in liver transplant recipients. Transplant Proc 2002; 34: 15571558.
  • 61
    Canzanello VJ, Schwartz L, Taler SJ, Textor SC, Wiesner RH, Porayko MK, Krom RAF. Evolution of cardiovascular risk after liver transplantation: A comparison of cyclosporine A and tacrolimus (FK506). Liver Transpl Surg 1997; 3: 19.
  • 62
    Cai TH, Esterl RM Jr, Nichols L, Cigarroa F, Speeg KV, Halff GA. Improved immunosuppression with combination tacrolimus (FK506) and mycophenolic acid in orthotopic liver transplantation. Transplant Proc 1998; 30: 14131414.